Home > Groups > Yu WANG

Yu WANG, Ph. D.

Drug Discovery; Stem Cell and Regenerative Biology.


Staff: Dr. Yu Wang, Dr. Chen Zhao
Students: Fujia Wu, Chenze Zhang, Li Chen, Ju Zhang, Yuhong Hou, Hao Wu, Shixian Wei, Chenxu Zhao

WANG Group website

 



HIT: novel drug inducible CRISPR/Cas9 and TALE(N) systems for gene editing and transcriptional modulation.



The application of a novel protein labeling technology in the mechanistic study of pharmacological modulation of a stem cell signaling pathway



The application of novel High Content Screening (HSC) technology in stem cell drug discovery

Plain english:
  Our lab is dedicated in interdisciplinary research of pharmacology and stem cell biology. We are committed to discovering new mechanisms, new therapeutic targets, and eventually new drugs for cancer and regenerative medicine. Meanwhile, we are strongly interested in developing novel and useful chemical biology tools.

 

Selected publications:

  1. Zhao, C1., Zhao, Y1., Zhang, J1., Lu, J., Chen, L., Zhang, Y., Ying, Y., Xu, J. Wei, S., Wang, Y.* (2018) HIT-Cas9: a CRISPR/Cas9 Genome Editing Device Under Tight and Effective Drug Control. Molecular Therapy-Nucleic Acids. 1(13): 208-219.
  2. Zhao, C1., Zhang, Y1., Zhao, Y., Ying, Y., Ai, R., Zhang, J., Wang, Y.* (2018) Multiple Chemical Inducible Tal Effectors for Genome Editing and Transcription Activation. ACS Chemical Biology. 13(3): 609-617.
  3. Lu, J1., Zhao, C1., Zhao, Y1., Zhang, J1., Zhang, Y., Chen, L., Han, Q., Ying, Y., Peng, S., Ai, R., Wang, Y.* (2018) Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. Nucleic Acids Research 46(5): e25
  4. Liu, L., Zhang, J., Rheindt, F.E., Lei, F., Qu, Y., Wang, Y., Zhang, Y., Sullivan, C., Nie, W., Wang, J., Yang, F., Chen, J., Edwards, S.V., Meng, J., Wu, S., (2017) Genomic Evidence Reveals a Radiation of Placental Mammals Uninterrupted by the KPg Boundary. PNAS 114 (35):E7282-E7290.
  5. Wu, F., Zhang, Y., Sun, B., McMahon, A.P., Wang, Y.* (2017) Hedgehog Signaling: From Basic Biology to Cancer Therapy. Cell Chemical Biology. 24 (3): 252-280.
  6. Ding, H., Yang, D., Zhao, C., Song, Z., Liu, P., Wang, Y., Chen, Z., Shen, J. (2015) Protein?Gold Hybrid Nanocubes for Cell Imaging and Drug Delivery. ACS Appl. Mater. Interfaces 7 (8): 4713–4719.
  7. Schwartz, M.P., Hou, Z., Propson, N.E., Zhang, J., Engstrom, C.J., Costa, V.S., Jiang, P., Nguyen, B.K., Bolin, J.M., Daly, W., Wang, Y., Stewart, R., Page, C.D., Murphy, W.L., and Thomson, J.A. (2015) Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. PNAS 112 (40): 12516-12521.
  8. Wang, Y.*, and McMahon, A.P. (2013). A novel site comes into sight. eLife2, e01680.
  9. Wang, Y., Davidow, L., Arvanites, A.C., Blanchard, J., Lam, K., Xu, K., Oza, V., Yoo, J.W., Ng, J.M., Curran, T., Rubin, L.L. *, and McMahon, A.P*. (2012b). Glucocorticoid compounds modify smoothened localization and hedgehog pathway activity. Chemistry & biology19, 972-982.
  10. Wang, Y., Arvanites, A.C., Davidow, L., Blanchard, J., Lam, K., Yoo, J.W., Coy, S., Rubin, L.L. *, and McMahon, A.P*. (2012a). Selective identification of hedgehog pathway antagonists by direct analysis of smoothened ciliary translocation. ACS chemical biology7, 1040-1048.
  11. Wang, Y., Zhou, Z., Walsh, C.T. *, and McMahon, A.P. * (2009). Selective translocation of intracellular Smoothened to the primary cilium in response to Hedgehog pathway modulation. PNAS106, 2623-2628.
  12. Wang, Y.1, McMahon, A.P. *, and Allen, B.L. 1 (2007). Shifting paradigms in Hedgehog signaling. Current opinion in cell biology19, 159-165.

Patent:

  1. Wang Y and McMahon AP (2013). System for screening agonists/antagonists of cellular signaling pathways. US Patent 8,574,837.
  2. Wang Y, McMahon AP, and Rubin LL (2013). Modulators of Hedgehog signaling pathway. US Patent App. 20,130,274,233.
  3. Wang Y, Lu J, Zhao C, Zhang J (2017). Drug inducible CRISPR/Cas devices for transcriptional activation. Patent App., 201710553184.8.
  4. Wang Y, Zhao C, Lu J, Zhao Y, Zhang J (2017). Drug inducible CRISPR/Cas devices for transcriptional modulation and genome editing. Patent App., 201710553178.2.
  5. Wang Y, Zhao C, Zhang Y (2017). Coding genes of drug inducible fusion proteins and their application for genome editing. Patent App., 201710549795.5.
  6. Wang Y, Zhao C, Zhang Y (2017). Methods for drug inducible transcriptional activation. Patent App., 201710553173.X.